DOW JONES27,960.80-1031.61 -3.56%
S&P 5003,225.89-111.86 -3.35%
NASDAQ9,221.28-355.31 -3.71%

UPDATE: Cantor Fitzgerald Maintains Overweight On Aimmune Therapeutics, Raises Target To $64 After FDA Approves PALFORZIA For The Treatment Of Peanut Allergy In Patients Between Ages 4-17

Benzinga · 02/03/2020 12:23